Update on Hepatitis C Vaccine: Results and Challenges

Area of Science:

• Hepatology and Viral Immunology
• Vaccine Development
• Infectious Disease Research

Background:

• Direct-acting antiviral drugs (DAAs) have revolutionized Hepatitis C virus (HCV) therapy, achieving high sustained virological response (SVR) rates.
• Despite DAA success, an effective anti-HCV vaccine is needed due to limited DAA treatment access and HCV reinfections in high-risk populations.

Purpose of the Study:

• To review current strategies for developing an effective anti-HCV vaccine.
• To evaluate the efficacy of B-cell and T-cell based vaccine approaches against HCV.

Main Methods:

• Analysis of vaccine strategies targeting E1 and E2 proteins for B-cell mediated immunity.
• Review of viral vector-based approaches for eliciting T-cell immune responses against HCV.

Main Results:

• E1/E2 protein vaccines induce cross-neutralizing antibodies against multiple HCV genotypes, but protection is incomplete and antibody levels are often insufficient.
• HCV-specific T-cell responses show sustained expansion of effector memory T cells, improved proliferation, and polyfunctionality, yet remain limited in frequency and effectiveness.

Conclusions:

• Current anti-HCV vaccine strategies, targeting either B-cell or T-cell responses, have shown progress but have not yet achieved full protective immunity.
• Further research is needed to enhance the breadth, potency, and durability of immune responses elicited by HCV vaccines to overcome existing challenges.